Katherine Taudvin

CIMA Labs, Inc. develops and manufactures prescription and over-the-counter pharmaceutical products using fast-dissolve drug delivery technologies. It develops orally disintegrating technology based OraSolv and DuraSolv tablets. It also develops tranmucosal tablets that can be administered sublingually. The company is headquartered in Brooklyn Park, MN.

ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ.

Thesan Pharmaceuticals, Inc. provides novel therapeutics for disorders of the skin. The company focuses on the discovery and development of new chemical entities that provide improved treatment options to patients. Thesan Pharmaceuticals was founded in 2011 by Edward P. Monaghan and is headquartered in Carlsbad, CA.

Prevacus, Inc. is engaged in biotechnology services. The company was founded by Jacob Vanlandingham and is headquartered in Tallahassee, FL.

Navitor Pharmaceuticals, Inc. develops medicine for age-related diseases. Its drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. The company was founded by Alan L. Crane, David Sabatini and David Goldfarb and is headquartered in Cambridge, MA.

C.W. Obel A/S provides investment services to industrial companies. The firm's financial assets are located in collaboration with independent financial advisor used by banks and pension companies. The company was founded by Christen Winther Obel in 1787 and is headquartered in Copenhagen, Denmark.

Part of Universal Music Group NV, CMC is a Danish company that publishes music records. The company is located in Denmark. CMC was acquired by EMI Group Ltd., part of Universal Music Group NV from June 29, 2012 on November 01, 1997.

Symbion A/S provides office communities, meeting facilities, conference facilities, business development and capital for start-up companies. The company was founded in 1986 and is headquartered in Copenhagen, Denmark.

KLIFO A/S provides clinical research services. Its services include development plans, protocols, project management, monitoring, data management and statistics, reporting, regulatory affairs, importing, packaging, labeling, and distribution of clinical trials. The company provides services to the pharmaceutical and medical devices industries. KLIFO was founded by Dr. Allan Rosetzsky in 1994 and is headquartered in Copenhagen, Denmark.

7TM A/S performs research and development within biotechnology. It engages in clinical development of drugs focusing on obesity and gastrointestinal diseases. The company was founded by Thue Walter Schwartz, Anders Fink Vadsholt, Mette Kirstine Agger, Christian Ellebæk Elling, and Peter Moldt on January 1, 2000 and is headquartered in Hørsholm, Denmark.

Sophion Bioscience A/S develops, manufactures and markets instruments and supplies automated patch clamping. It develops throughput patch clamp solutions for functional characterization of living cells. The firm products are used in pharmaceutical and biotech companies around the world. The company was founded in July 2007 and is headquartered in Ballerup, Denmark.

DySIS Medical Ltd. designs, develops, manufactures, and markets medical imaging systems. Its imaging systems assist clinicians with non-invasive, in-vivo detection of cancerous and pre-cancerous lesions and provides tools to aid medical practitioners in the detection, grading, and documentation of cervical neoplasia. The company was founded by Costas Balas in 2002 and is headquartered in Livingston, the United Kingdom.

AlloCure, Inc. develops cell therapies for the treatment of kidney diseases. It engages in developing allogeneic mesenchymal stem cell therapy for acute kidney injury. The company was founded in 2008 and is headquartered in Burlington, MA.

EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark.

CeQur SA develops medical devices for diabetes patients. It offers n insulin delivery device that provides three days of consistent, basal insulin deliver along with on-demand bolus insulin. The company was founded by James L. Peterson in January 2008 and is headquartered in Horw, Switzerland.

Lundbeckfonden Ventures (Lundbeckfonden Ventures) is a venture capital firm wholly-owned by the Lundbeck Foundation. The firm was established in 2009 and is headquartered in Copenhagen, Denmark.

Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom.

Cydan LLC operates as an orphan drug accelerator that identifies and de-risks programs. The firm's model evaluates programs for treating rare diseases with unmet medical need and is aimed at creating new companies to develop those therapies. The company was founded by James G. McArthur in 2013 and is headquartered in Cambridge, MA.

New Rhein Healthcare Investors LLC (New Rhein Healthcare Investors) is a private equity firm founded in 2010 by Parekh Greg. The firm is headquartered in Philadelphia, Pennsylvania.

Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD.

Abzu ApS provides technology services. It offers Abzu AI platform. The firm specializes in data, deep and machine learning, AI platform, cell based model, predictive problems and artificial general intelligence. The company was founded by Casper Skern Wilstrup in January 2018 and is headquartered in Copenhagen, Denmark.

Tiburio Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It provides novel treatments for rare neuroendocrine tumors and endocrine diseases. The company was founded by James Gregg McArthur in January 2019 and is headquartered in Cambridge, MA.